Literature DB >> 8027502

IgE-binding capacity of recombinant timothy grass (Phleum pratense) pollen allergens.

S Laffer1, S Vrtala, M Duchêne, R van Ree, D Kraft, O Scheiner, R Valenta.   

Abstract

A panel of 60 cDNA clones coding for IgE-binding proteins from timothy grass pollen was immunocharacterized with sera from 30 patients allergic to grass pollen and antibodies raised against natural grass pollen allergens. In the cases of five representative patients in whom the IgE reactivity pattern with the recombinant allergens had been determined, IgE immunoadsorption experiments were performed. Recombinant Phl p I, Phl p V, and Phl p II and recombinant timothy grass profilin were used for immunoadsorption of the sera, and the percentage of remaining grass pollen-specific IgE was estimated. Although most of the patients showed IgE reactivity to a number of different natural and recombinant timothy grass pollen allergens, up to 66% of IgE directed against blotted total natural grass pollen allergens could be immunoadsorbed from the sera with recombinant Phl p V and Phl p I. The data point to the usefulness of recombinant allergens not only to determine IgE specificities of allergic patients but also to estimate the percentage of specific IgE that individuals produce against certain allergens. The fact that only a limited number of recombinant timothy grass pollen allergens account for a high percentage of grass pollen-specific IgE points to the possible usefulness of recombinant allergens not only for in vitro diagnosis but probably also for specific immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8027502     DOI: 10.1016/0091-6749(94)90075-2

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  7 in total

1.  Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.

Authors:  Margarete Focke-Tejkl; Milena Weber; Katarzyna Niespodziana; Angela Neubauer; Hans Huber; Rainer Henning; Gottfried Stegfellner; Bernhard Maderegger; Martina Hauer; Frank Stolz; Verena Niederberger; Katharina Marth; Julia Eckl-Dorna; Richard Weiss; Josef Thalhamer; Katharina Blatt; Peter Valent; Rudolf Valenta
Journal:  J Allergy Clin Immunol       Date:  2014-11-13       Impact factor: 10.793

2.  A folded and immunogenic IgE-hyporeactive variant of the major allergen Phl p 1 produced in Escherichia coli.

Authors:  Mattias Levin; Harm Otten; Claes von Wachenfeldt; Mats Ohlin
Journal:  BMC Biotechnol       Date:  2015-06-09       Impact factor: 2.563

3.  Plant Stress Scenarios Differentially Affect Expression and IgE Reactivity of Grass Group-1 Allergen (β-Expansin) in Maize and Rice Pollen.

Authors:  Yotin Juprasong; Wisuwat Songnuan
Journal:  Front Allergy       Date:  2022-02-10

Review 4.  Multiple grass mixes as opposed to single grasses for allergen immunotherapy in allergic rhinitis.

Authors:  K Gangl; V Niederberger; R Valenta
Journal:  Clin Exp Allergy       Date:  2013-11       Impact factor: 5.018

5.  Sensitization to timothy grass pollen allergenic molecules in children.

Authors:  Alessandra Scaparrotta; Marcello Verini; Nicola Pietro Consilvio; Anna Cingolani; Daniele Rapino; Marina Attanasi; Marzia Cerasa; Sabrina Di Pillo; Francesco Chiarelli
Journal:  Multidiscip Respir Med       Date:  2013-03-01

6.  Hypersensitivity to major panallergens in a population of 120 patients.

Authors:  Eleonora Nucera; Simona Mezzacappa; Arianna Aruanno; Valentina Pecora; Angela Rizzi; Anna Giulia Ricci; Manuela Ferraironi; Alessandro Buonomo; Domenico Schiavino
Journal:  Postepy Dermatol Alergol       Date:  2015-08-12       Impact factor: 1.837

7.  The Occurrence of Food Hypersensitivity Reactions and the Relation to the Sensitization to Grass and Trees in Atopic Dermatitis Patients 14 Years of Age and Older.

Authors:  Jarmila Celakovská; Josef Bukac; Karel Ettler; Jaroslava Vaneckova; Irena Krcmova; Kvetuse Ettlerova; Jan Krejsek
Journal:  Indian J Dermatol       Date:  2019 Sep-Oct       Impact factor: 1.494

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.